DRMA Company Profile and Key Details

Dermata Therapeutics, Inc. generated EPS of -$20.29 over the past year. Five-year average earnings growth is 43.22%. The latest quarter delivered EPS of -$1.65. The next quarter is forecast at -$1.54. Next year's EPS is expected at $44.31. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $10.00. The high target offers 418.13% upside. The low target suggests 418.13% downside. The mean target is $10.00. This offers 418.13% upside. Dermata Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 14, 2025, missed forecasts by 3.77%. The prior quarter beat by -42.76%. Over the last six quarters, Apple has recorded several small beats. These include 10.29% in August 07, 2024.

DRMA has shown mixed momentum, gaining 19.23% over the past week and -45.34% over the past quarter, though year-to-date performance is down -6.47%. Short-term trend indicators are bullishly aligned (SMA20 -37.24%, SMA50 -42.47%, SMA200 -73.93%). The stock’s 14-day RSI is 35.05 (weak momentum), while the ATR of 0.33 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -94.68% below its high and over -2.33% above its low. Average 10-day trading volume of 4.64 million shares is significantly above the 3-month average of 2.02 million, indicating heightened recent market interest.

Dermata Therapeutics, Inc. has 681.56 thousand shares outstanding. The public float is 498.47 thousand shares, elevated short interest at 3.23% of float. This equals 13.00 thousand shares. The short ratio is 0.44 days. Institutional investors hold 8.98% of the float. Insiders own 17.0%.

Dermata Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $20.66. This means the shares are trading below this model’s fair value.

Dermata Therapeutics, Inc. (NASDAQ:DRMA) closed at $1.93 USD, gaining $0.65 (50.78%) from the previous close of $1.28. The stock is currently mid-range between its 52-week high and low $1.29 and $23.70. With a market capitalization of about $1.32 million, Dermata Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.55). Key stats such as the average daily volume over the past year has been around 1.54 million shares, trading with heavier-than-usual volume. Headquartered in San Diego, CA, Dermata Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Gerald T. Proehl, the company employs approximately 8 people and listed since August 13, 2021. Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions.

Dermata Therapeutics, Inc. (NASDAQ:DRMA) shares are flat -6.47% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Dermata Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.18. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $6.67, suggesting 245.6% upside. Our AI forecast model points to short-term weakness (-43.01% over two weeks), a medium-term fall (-88.6% over three months), and a longer-term gain (190.67% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Dermata Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -43.01%, with price expected at $1.10 by March 04, 2026, within a range of $0.69 to $1.50 3-Month Outlook: Projected fall of -88.6%, reaching $0.22 by May 19, 2026, with a range of $0.00 to $1.45. 1-Year Outlook: Projected gain of 190.67%, with price at $5.61 by February 18, 2027, within a range of $4.05 to $7.45.

Dermata Therapeutics, Inc. trades at a P/E ratio of -0.18, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.4 suggesting the stock is closer to book value. The P/FCF stands at -0.11, also above market averages.